Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of an Engineered, Liver-Tropic Adeno-Associated Virus Vector Expressing Factor IX Padua Administered with Prophylactic Glucocorticoids in Patients with Hemophilia B: A Multi-Center, Single-Arm, Phase 3 Trial

Feng Xue, Mankai Ju, Tienan Zhu, ZePing Zhou, Jing Sun, Linhua Yang, Zhenyu Yan, Hu Zhou, Xin Du, Changcheng Zheng, Xia Wu, Xiao Xiao, Renchi Yang, Lei Zhang

Blood (2024) 144 (Supplement 1): 3582.

https://doi.org/10.1182/blood-2024-204715

Published: 2024

Journal Articles

A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

David J Kuter, Tomas Jose Gonzalez Lopez, Karolin Trautmann-Grill, Mathias J. Rummel, Philip Young-Ill Choi, Alessandra Borchiellini, Muhlis Cem Ar, Huyen Tran, Tienan Zhu, Jae-Ho Yoon, Nichola Cooper, Thomas Stauch, Pinar Tarkun, Fabienne Le Gac, Alex Allepuz, Patrick Urban, Renxin Lin, Charlotte A. Bradbury

Blood (2024) 144 (Supplement 1): 710.

https://doi.org/10.1182/blood-2024-201418

Published: 2024

Journal Articles

A Prospective Phase II Study of Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Idiopathic Multicentric Castleman's Disease

Lu Zhang, MD, Ai-lin Zhao, MD, Jun Feng, MD, Xinxin Cao, MD, Yan Zhang, MD, Tienan Zhu, MD, Minghui Duan, MD, Daobin Zhou, MD, Jian Li, MD

Blood (2018) 132 (Supplement 1): 4142.

https://doi.org/10.1182/blood-2018-99-113528

Published: 2018

Journal Articles

Antithrombin, Protein C, Protein S and Activated Protein C Resistance in the General Healthy Chinese Population: Normal Plasmatic Ranges and Genetic Defects.

Yongqiang Zhao, MD, Xuefeng Wang, MD, Qiulan Ding, MD, Xuqian Wei, MD, Tienan Zhu, MD, Florentia Kaguelidou, MD, Renchi Yang, MD, Changgeng Ruan, MD, Zhaoyue Wang, MD, Xia Bai, MD, Nicole Schlegel, MD

Blood (2007) 110 (11): 3982.

https://doi.org/10.1182/blood.V110.11.3982.3982

Published: 2007

Journal Articles

Treatment of Primary Central Nervous System Lymphoma with a Combination of Intraventricular Administration of Rituximab and Systemic Chemotherapy.

Shujie Wang, MD, PhD, Wei Zhang, MD, Wei Lian, MD, Yongji Wu, MD, Nong Zou, MD, Tienan Zhu, MD, Daobin Zhou, MD, Ying Xu, MD, Ti Shen, MD, Yongqiang Zhao, MD, PhD

Blood (2006) 108 (11): 4695.

https://doi.org/10.1182/blood.V108.11.4695.4695

Published: 2006

Journal Articles

Multiple Cycles of Recombinant Human Thrombopoietin Therapy in a Patient with Chronic Refractory Idiopathic Thrombocytopenic Purpura.

Yongqiang Zhao, MD, Baolai Hua, MD, Nong Zou, MD, Shujie Wang, MD, Tienan Zhu, MD

Blood (2004) 104 (11): 3933.

https://doi.org/10.1182/blood.V104.11.3933.3933

Published: 2004

NARROW

Efficacy and Safety of an Engineered, Liver-Tropic Adeno-Associated Virus Vector Expressing Factor IX Padua Administered with Prophylactic Glucocorticoids in Patients with Hemophilia B: A Multi-Center, Single-Arm, Phase 3 Trial

A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

A Prospective Phase II Study of Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Idiopathic Multicentric Castleman's Disease

Antithrombin, Protein C, Protein S and Activated Protein C Resistance in the General Healthy Chinese Population: Normal Plasmatic Ranges and Genetic Defects.

Treatment of Primary Central Nervous System Lymphoma with a Combination of Intraventricular Administration of Rituximab and Systemic Chemotherapy.

Multiple Cycles of Recombinant Human Thrombopoietin Therapy in a Patient with Chronic Refractory Idiopathic Thrombocytopenic Purpura.

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety of an Engineered, Liver-Tropic Adeno-Associated Virus Vector Expressing Factor IX Padua Administered with Prophylactic Glucocorticoids in Patients with Hemophilia B: A Multi-Center, Single-Arm, Phase 3 Trial

A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

A Prospective Phase II Study of Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Idiopathic Multicentric Castleman's Disease

Antithrombin, Protein C, Protein S and Activated Protein C Resistance in the General Healthy Chinese Population: Normal Plasmatic Ranges and Genetic Defects.

Treatment of Primary Central Nervous System Lymphoma with a Combination of Intraventricular Administration of Rituximab and Systemic Chemotherapy.

Multiple Cycles of Recombinant Human Thrombopoietin Therapy in a Patient with Chronic Refractory Idiopathic Thrombocytopenic Purpura.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only